Person: ZARİFOĞLU, MEHMET
Loading...
Email Address
Birth Date
11 results
Search Results
Now showing 1 - 10 of 11
Publication The expression and prognostic value of miR-146a and miR-155 in Turkish patients with multiple sclerosis(Taylor & Francis, 2022-03-04) Sarıdaş, Furkan; Ünlü, Havva Tezcan; Çeçener, Gülşah; Egeli, Ünal; Takanlou, Maryam Sabour; Takanlou, Leila Sabour; Tunca, Berrin; Zarifoğlu, Mehmet; Turan, Ömer Faruk; Taşkapılıoğlu, Özlem; SARIDAŞ, FURKAN; ÇEÇENER, GÜLŞAH; EGELİ, ÜNAL; TUNCA, BERRİN; ZARİFOĞLU, MEHMET; TURAN, ÖMER FARUK; Takanlou, Maryam Sabour; Takanlou, Leila Sabour; Taşkapılıoğlu, Özlem; 0000-0001-5945-2317; 0000-0002-0910-4258; 0000-0002-3820-424X; 0000-0001-7904-883X; 0000-0002-1590-4833; 0000-0002-6361-7150; 0000-0002-1619-6680; HSB-2700-2023; GYU-0252-2022; AAP-9988-2020; AAH-1420-2021; KGL-6846-2024; GRE-6268-2022; ABI-6078-2020; EHN-5825-2022; JDI-6091-2023; EBA-4926-2022Multiple sclerosis (MS) is an inflammatory, autoimmune demyelinating, and neurodegenerative disorder of the central nervous system. Interactions between environmental factors, predisposition genes, and determining genes appear to be involved in its etiology. Epigenetic mechanisms such as microRNA-mediated gene regulation can determine the susceptibility and severity of autoimmune diseases. Therefore, to determine the role of miR-146a and miR-155 in MS and its developmental stages, the expression levels in the serum of MS and clinically isolated syndrome (CIS) patients were compared with those of healthy controls. In the present study, the expression levels of miR-146a and miR-155 were assessed using quantitative Real-Time PCR in blood samples of 15 CIS patients and 61 relapsing-remitting multiple sclerosis (RRMS) patients alongside 32 healthy patients as controls. Furthermore, any associations with the clinicopathologic variables of the patients were also evaluated. Dysregulations were found only in the miR-146a and miR-155 expressions in the RRMS-Control group. When the RRMS patients were evaluated in terms of the characteristics of sex, annual attack rate, age of diagnosis, duration of follow-up, and immunomodulatory treatments used, no significant differences were observed. However, significant dysregulations were identified in miRNA expression in the vitamin D level, EDSS values, and the number of attacks. ROC curve analysis showed that miR-146a and miR-155 were significant in the RRMS-Control group for the area under the curve (AUC). It is possible that miR-146a may be associated with vitamin D deficiency and disease disability, while miR-155 may be associated with the number of attacks.Publication Clinical characteristics and burden of a large series with cluster headache from Turkey(Sage Publications, 2021-09-01) Dikmen, P. Yalinay; Ari, C.; Sahin, E.; Ertas, M.; Domac, F. Mayda; Aydinlar, E. Ilgaz; Sahin, A.; Ozge, A.; Ozguner, H.; Karadas, O.; Shafiyev, J.; Vuralli, D.; Bolay, H.; Ekizoglu, E.; Orhan, E. Kocasoy; Baykan, B.; Akarsu, E. Oguz; OĞUZ AKARSU, EMEL; Karli, N.; BAYSAL KAR, BAHAR; Zarifoglu, M.; ZARİFOĞLU, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; 0000-0001-7112-2142; 0000-0002-2354-2975; 0000-0002-5792-2888; 0000-0002-3334-979X; 0000-0002-3360-659X; AFB-2183-2022; HGA-8185-2022; HRC-1114-2023; A-4787-2018; GXV-0461-2022; IZQ-0662-2023Publication The role of the dopamine β-hydroxylase functional polymorphism in patients with early-onset parkinson's disease in the Turkish population(Turkish Neurological Soc, 2021-03-01) Erer, Sevda; Eryılmaz, Işıl Ezgi; Çolak, Dilara Kamer; Egeli, Ünal; Çeçener, Gülşah; Tunca, Berrin; Karakuş, Ece; Çolakoğlu, Beril; Tokçaer, Ayşe Bora; Saka, Esen; Demirkıran, Meltem; Akbostancı, Cenk; Zarifoğlu, Mehmet; Doğu, Okan; Kaleagasi, Hakan; Kenangil, Gülay; Çakmur, Raif; Elibol, Bülent; ERER ÖZBEK, ÇİĞDEM SEVDA; ERYILMAZ, IŞIL EZGİ; Çolak, Dilara Kamer; EGELİ, ÜNAL; ÇEÇENER, GÜLŞAH; TUNCA, BERRİN; Karakuş, Ece; ZARİFOĞLU, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0001-7904-883X; 0000-0002-3316-316X; 0000-0002-2274-3230; 0000-0003-4968-2826; 0000-0002-3820-424X; 0000-0002-1619-6680; 0000-0003-2982-0961; GWV-3548-2022; AAH-1420-2021; DVY-9744-2022; JIP-4494-2023; AAP-9988-2020; ABI-6078-2020; FDA-2023-2022; EHN-5825-2022Objective: A functional single nucleotide polymorphism, rs1611115, in the dopamine beta-hydroxylase (DBH) gene, is reported to regulate plasma enzyme activity levels. Mere, we report the first evaluation of this association in patients with early-onset Parkinson's disease (EOPD) and healthy controls in the Turkish population.Materials and Methods: We evaluated the DBH rs1611115 polymorphism in 114 (64 male and 50 female) Turkish patients with EOPD and 58 sex- and age-matched healthy controls from the Turkish population. A total of 27.2% (n=31) of our patients who had any variation including pathogenic or non-pathogenic missense, non-sense and/or intronic variation with unknown significance in EOPD genes were grouped as "variation-positive EOPD". A total of 50.8% (n=58) of our patients were grouped as "variation and family history-negative EOPD" and the possible contribution of the DBH rs1611115 polymorphism to EOPD pathogenesis was evaluated in this group.Results: There was no significant difference in the genotypic and allelic frequencies of DBH rs1611115 between patients with EOPD and controls. To our knowledge, this is the first evaluation of the DBH rs1611115 polymorphism in patients with EOPD and ethnically matched controls in the Turkish population.Conclusion: Some previous studies have reported conflicting association results between DBH rs1611115 polymorphism and PD pathogenesis in different ethnic groups. Therefore, further studies are needed to evaluate dopamine metabolism-related generic variants and to determine their possible roles in EOPD susceptibility in the Turkish population.Publication Insight into pain syndromes in acute phase of mild-to-moderate covid-19: Frequency, clinical characteristics, and associated factors(Wiley, 2021-10-26) Karli, Necdet; KARLI, HAMDİ NECDET; Gullu, Gizem; GÜLLÜ, GİZEM; Kilic, Erhan; KILIÇ, ERHAN; Dinc, Yasemin; DİNÇ, YASEMİN; Ursavas, Ahmet; URSAVAŞ, AHMET; Yilmaz, Emel; YILMAZ, EMEL; Zarifoglu, Mehmet; ZARİFOĞLU, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-3894-1231; IUQ-6999-2023; AAI-3169-2021; IZQ-0662-2023; AAD-1271-2019Background Pain has been frequently described as a clinical feature of COVID-19, and the main pain syndromes that have been associated with the acute phase of this disease so far are headache, myalgia, arthralgia, and neuropathic pain. Understanding the characteristics of pain symptoms is crucial for a better clinical approach. Methods Patients who were diagnosed as having COVID-19 using reverse transcription-polymerase chain reaction were included in the study. Patients were asked to complete a 51-item questionnaire via a phone interview, which included questions on demographics, acute COVID-19 symptoms, the presence of pain symptoms, and their characteristics in the acute phase of COVID-19. Results A total of 222 out of 266 patients with COVID-19 participated in the study, yielding a response rate of 83.5%. A total of 159 patients reported at least one kind of pain syndrome with a prevalence of 71.6%. Myalgia was reported in 110 (49.6%) patients, headache in 109 (49.1%), neuropathic pain symptoms in 55 (24.8%), and polyarthralgia in 30 (13.5%) patients. A total of 66 patients reported only one type of pain, 46 reported two types, 42 reported three types, and five patients reported all four types of pain. Logistic regression analysis showed that there were significant associations between these pain syndromes and a strong association was found between neuropathic pain and headache. Conclusion Pain is a frequently observed symptom of mild-to-moderate COVID-19. There are significant relationships between pain syndromes in COVID-19, which may be due to a sequence of common etiologic factors. Significance This study described the main pain syndromes associated acute phase of mild-to-moderate COVID-19 and its associated features. Headaches and pain of neuropathic characteristics were prevalent in this sample.Publication Contribution of functional dopamine D2 and D3 receptor variants to motor and non-motor symptoms of early onset Parkinson's disease(Elsevier, 2020-09-28) Eryılmaz, Işıl Ezgi; Erer, Sevda; Zarifoğlu, Mehmet; Egeli, Ünal; Karakuş, Ece; Yurdacan, Beste; Çeçener, Gülşah; Tunca, Berrin; Çolakoğlu, Beril; Tokcaer, Ayşe Bora; Saka, Esen; Demirkıran, Meltem; Akbostancı, Cenk; Doğu, Okan; Kaleağası, Hakan; Kenangil, Gülay; Çakmur, Raif; Elibol, Bülent; ERYILMAZ, IŞIL EZGİ; ERER ÖZBEK, ÇİĞDEM SEVDA; ZARİFOĞLU, MEHMET; EGELİ, ÜNAL; Karakuş, Ece; Yurdacan, Beste; ÇEÇENER, GÜLŞAH; TUNCA, BERRİN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-3316-316X; 0000-0001-7904-883X; 0000-0002-3820-424X; 0000-0002-1619-6680; GWV-3548-2022; DVY-9744-2022; EHN-5825-2022; AAH-1420-2021; FDA-2023-2022; AEA-0144-2022; AAP-9988-2020; ABI-6078-2020In the present study, we focused on investigating the contribution of functional dopamine D2 and D3 receptor variants to motor and/or non-motor symptoms of early onset Parkinson's disease (EOPD). Three functional single nucleotide polymorphisms (SNPs), DRD3 rs6280, DRD2 rs2283265 and DRD2 rs1076560, were genotyped in 128 Turkish EOPD patients and then, statistical analysis was conducted for the potential impacts of SNPs on clinical parameters. All three SNPs were found to be statistically significant in terms of PD-related pain: DRD3 [rs6280; risk allele "T" for pain; p = 0.031; odds ratio (OR)=4.25], DRD2 [rs2283265; risk allele "A" for pain; p = 0.001; OR=8.47] and, DRD2 [rs1076560; risk allele "A" for pain; p = 0.022; OR=4.58]. Additionally, bilateral disease [p = 0.011; OR=5.10] and gender [risk group "female"; p = 0.003; OR=8.53] were also identified as significant univariate risk factors for PD-related pain. Based on logistic regression analysis conducted with the significant univariate risk factors, this the first report to clarify that a female patient with bilateral PD and DRD2 rs2283265 polymorphism has a significant risk for PD-related pain. Our findings might contribute to improve life quality by offering treatment options for pain in PD patients with these clinical and genetic features.Publication Evaluation of the effects of botulinum toxin therapy on the clinical characteristics of pain and pain threshold value in patients with primary cervical dystonia(Journal Neurological Sciences, 2015-01-01) Özbek, Sevda Erer; Karlı Necdet; Yurtoğulları, Şükran; Zarifoğlu, Mehmet; Ocakoğlu, Gökhan; ERER ÖZBEK, ÇİĞDEM SEVDA; KARLI, HAMDİ NECDET; YURTOĞULLARI, ŞÜKRAN; ZARİFOĞLU, MEHMET; OCAKOĞLU, GÖKHANObjective: In 70% of patients with cervical dystonia (CD), the clinical presentation includes the symptom of pain. In this study, we aimed to define the types and clinical characteristics of the pain and to investigate whether this pain is a result of central sensitization by evaluating pre- and post-botulinum toxin (BoNT) treatment pain threshold values using electrical stimulation.Methods: The study enrolled a total of 35 patients with CD who received BoNT therapy. The patients were evaluated using the pain evaluation scale and Unified Dystonia Rating scale (UDRS) before and after BoNT therapy. The pain threshold values obtained from dystonic muscles, the contiguous or contralateral muscle without dystonic activity and a normal reference muscle with distant localization were recorded through electrical stimulation with EMG guidance, and all values obtained before and after BoNT therapy were compared.Results: No difference was found between the pain threshold values obtained from dystonic muscles before and after treatment. While no difference was observed across genders or VAS groups in terms of pain threshold values, the UDRS (duration and motor severity factor) scores showed significant decreases after treatment with BoNT in patients with painful dystonia and in patients with painless dystonia.Conclusions: The absence of a difference in pre- and post-BoNT treatment pain threshold values in dystonic muscles might be explained by the absence of central sensitization. Pain relief in dystonic patients might occur secondary to decreases in dystonic muscle contractions.Publication Association of headache prevalance with early menarche in female medical students(Sage, 2015-05-01) Özyurtlu, D.; Karlı, Nejdet; Zarifoğlu, Mehmet; Özkaya, Güven; Özyurtlu, D.; Karlı, Nejdet; ZARİFOĞLU, MEHMET; ÖZKAYA, GÜVEN; Uludağ Üniversitesi; 0000-0003-0297-846X; A-4421-2016; FQO-3662-2022; CXD-7623-2022; EHN-5825-2022Publication Course of migraine and TTH over the years - what happens? A longitudinal nationwide study(Lippincott Williams & Wilkins, 2016-04-05) Karlı, Necdet; Baykan, Betül; Zarifoğlu, Mehmet; Ertaş, Mustafa; Uludüz, Derya; Uygunoğlu, Uğur; Ekizoğlus, Esme; Orhan, Elif; Saip, Sabahattin; Siva, Aksel; ZARİFOĞLU, MEHMET; Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; EHN-5825-2022Publication The distinct genetic pattern of als in turkey and novel mutations(Elsevier Science, 2015-04-01) Özoğuz, Aslıhan; Uyan, Özgün; Birdal, Güneş; İskender, Ceren; Kartal, Ece; Lahut, Suna; Ömür, Özgür; Ağım, Zeynep Sena; Eken, Aslı Gündoğdu; Sen, Nesli Ece; Kavak, Pınar; Saygi, Ceren; Sapp, Peter C.; Keagle, Pamela; Parman, Yesim; Tan, Ersin; Koc, Filiz; Deymeer, Feza; Oflazer, Piraye; Hanagasi, Hasmet; Gurvit, Hakan; Bilgic, Basar; Durmus, Hacer; Ertas, Mustafa; Kotan, Dilcan; Akalin, Mehmet Ali; Gulluoglu, Halil; Zarifoglu, Mehmet; Aysal, Fikret; Dosolu, Nilgun; Bilguvar, Kaya; Gunel, Murat; Keskin, Ozlem; Akgun, Tahsin; Ozcelik, Hilmi; Landers, John E.; Brown, Robert H.; Basak, A. Nazli; ZARİFOĞLU, MEHMET; Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; EHN-5825-2022The frequency of amyotrophic lateral sclerosis (ALS) mutations has been extensively investigated in several populations; however, a systematic analysis in Turkish cases has not been reported so far. In this study, we screened 477 ALS patients for mutations, including 116 familial ALS patients from 82 families and 361 sporadic ALS (sALS) cases. Patients were genotyped for C9orf72 (18.3%), SOD1 (12.2%), FUS (5%), TARDBP (3.7%), and UBQLN2 (2.4%) gene mutations, which together account for approximately 40% of familial ALS in Turkey. No SOD1 mutations were detected in sALS patients; however, C9orf72 (3.1%) and UBQLN2 (0.6%) explained 3.7% of sALS in the population. Exome sequencing revealed mutations in OPTN, SPG11, DJ1, PLEKHG5, SYNE1, TRPM7, and SQSTM1 genes, many of them novel. The spectrum of mutations reflect both the distinct genetic background and the heterogeneous nature of the Turkish ALS population. (C) 2015 Elsevier Inc. All rights reserved.Publication The role of obstructive sleep apnea syndrome as a cause of stroke(Galenos Publ House, 2015-09-01) SARIDAŞ, FURKAN; BİCAN DEMİR, AYLİN; Demir, Aylin Bican; Zarifoğlu, Mehmet; ZARİFOĞLU, MEHMET; Bora, İbrahim; BORA, İBRAHİM HAKKI; 0000-0001-5945-2317; 0000-0001-6739-8605; JCE-6657-2023; HSB-2700-2023; V-7170-2017Obstructive sleep apnea syndrome (OSAS) is a highly prevalent sleep disorder. Stroke is the second leading cause of death and the third leading cause of disability in the world. OSAS and stroke has common risk factors, are associated with each other and are both reported to play an important role in the etiology of each other. OSAS and stroke association was identified in our two cases in whom sleep-related respiratory problems were encountered before stroke. We would like to draw attention to the importance of OSAS being among the risk factors in the etiopathogenesis of stroke.